Literature DB >> 18977819

Alzheimer disease with cerebrovascular disease and vascular dementia: clinical features and course compared with Alzheimer disease.

A Bruandet1, F Richard, S Bombois, C A Maurage, V Deramecourt, F Lebert, P Amouyel, F Pasquier.   

Abstract

OBJECTIVE: Vascular dementia (VaD) and Alzheimer disease with cerebrovascular disease (AD+CVD) are the leading causes of dementia after Alzheimer disease alone (AD). Little is known about the progression of either VaD or AD+CVD. The aim of this study was to compare demographic features, cognitive decline and survival of patients with VaD, AD+CVD and AD alone attending a memory clinic.
METHODS: This study included 970 patients who were followed at the Lille-Bailleul memory clinic, France. Cognitive functions were measured with the Mini Mental State Examination (MMSE) and the Dementia Rating Scale (DRS). Survival rate was analysed with a left-truncated Cox model. Analyses were adjusted for age, sex, education, hypertension, diabetes and baseline MMSE and DRS.
RESULTS: Of 970 patients, 141 had VaD, 663 AD alone and 166 AD+CVD. The latter were significantly older than AD or VaD patients at onset (71 (SD 7) vs 69 (9) and 68 (9) years, p = 0.01) and at first visit (75 (6) vs 73 (8) and 72 (8) years, p = 0.0002). Baseline MMSE and DRS evaluations were highest for VaD compared with AD alone or AD+CVD patients (p<0.006). Cognitive decline during follow-up was slowest for VaD, intermediate for AD+CVD and fastest for AD alone (p = 0.03). After adjustment, compared with AD patients, mortality risk was similar for those with VaD (relative mortality risk (RR) = 0.7 (0.5 to 1.1)) and tended to be lower for AD+CVD (RR = 0.7 (0.5 to 1.0)). The shorter the delay between first symptoms and first visit, the longer patients survived.
CONCLUSION: This clinical cohort study shows that patients with VaD, AD+CVD and AD present different characteristics at baseline and during follow-up, and underlines the need to distinguish between them.

Entities:  

Mesh:

Year:  2008        PMID: 18977819     DOI: 10.1136/jnnp.2007.137851

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  29 in total

1.  Cerebral β-Amyloid Angiopathy Is Associated with Earlier Dementia Onset in Alzheimer's Disease.

Authors:  Eric D Vidoni; Hung-Wen Yeh; Jill K Morris; Kathy L Newell; Abdulfattah Alqahtani; Nicole C Burns; Jeffrey M Burns; Sandra A Billinger
Journal:  Neurodegener Dis       Date:  2016-01-13       Impact factor: 2.977

2.  Revised Framingham Stroke Risk Profile: Association with Cognitive Status and MRI-Derived Volumetric Measures.

Authors:  Isabelle Pelcher; Christian Puzo; Yorghos Tripodis; Hugo J Aparicio; Eric G Steinberg; Alyssa Phelps; Brett Martin; Joseph N Palmisano; Elizabeth Vassey; Cutter Lindbergh; Ann C McKee; Thor D Stein; Ronald J Killiany; Rhoda Au; Neil W Kowall; Robert A Stern; Jesse Mez; Michael L Alosco
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

3.  The association of age with rate of cognitive decline in elderly individuals residing in supporting care facilities.

Authors:  Ramit Ravona-Springer; Xiaodong Luo; James Schmeidler; Michael Wysocki; Gerson T Lesser; Michael A Rapp; Karen Dahlman; Hillel T Grossman; Vahram Haroutunian; Michal Schnaider Beeri
Journal:  Alzheimer Dis Assoc Disord       Date:  2011 Oct-Dec       Impact factor: 2.703

4.  Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

Authors:  Marie-Hélène Pilon; Stéphane Poulin; Marie-Pierre Fortin; Michèle Houde; Louis Verret; Rémi W Bouchard; Robert Laforce
Journal:  Neurology (ECronicon)       Date:  2016-03-11

5.  Insulin is differentially related to cognitive decline and atrophy in Alzheimer's disease and aging.

Authors:  Jeffrey M Burns; Robyn A Honea; Eric D Vidoni; Lewis J Hutfles; William M Brooks; Russell H Swerdlow
Journal:  Biochim Biophys Acta       Date:  2011-07-01

6.  Reasons that prevent the inclusion of Alzheimer's disease patients in clinical trials.

Authors:  Adeline Rollin-Sillaire; Laetitia Breuilh; Julia Salleron; Stéphanie Bombois; Pascaline Cassagnaud; Vincent Deramecourt; Marie-Anne Mackowiak; Florence Pasquier
Journal:  Br J Clin Pharmacol       Date:  2013-04       Impact factor: 4.335

Review 7.  The appropriate use of neuroimaging in the diagnostic work-up of dementia: an economic literature review and cost-effectiveness analysis.

Authors:  S L Bermingham
Journal:  Ont Health Technol Assess Ser       Date:  2014-02-01

Review 8.  Effects of stress and stress hormones on amyloid-beta protein and plaque deposition.

Authors:  Hongxin Dong; John G Csernansky
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

9.  Estimating regional cerebral blood flow using resting-state functional MRI via machine learning.

Authors:  Ganesh B Chand; Mohamad Habes; Sudipto Dolui; John A Detre; David A Wolk; Christos Davatzikos
Journal:  J Neurosci Methods       Date:  2019-11-19       Impact factor: 2.390

10.  The 5 Objects Test: a novel, minimal-language, memory screening test.

Authors:  Sokratis G Papageorgiou; Alexandra Economou; Christopher Routsis
Journal:  J Neurol       Date:  2013-12-27       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.